Condition: Atopic Dermatitis · Sponsor: Forte Biosciences, Inc.
The purpose of this study is to evaluate the continued safety and tolerability of FB-401 in subjects 2 years of age or older with mild to moderate atopic dermatitis. FB-401 will be applied topically for up to 48 additional weeks and subjects will be evaluated for safety.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Center for Dermatology Clinical Research, Inc. | Fremont, California, United States | — |
| Multi-Specialty Research Associates, Inc. | Lake City, Florida, United States | — |
| MedaPhase, Inc | Newnan, Georgia, United States | — |
| DS Research | Clarksville, Indiana, United States | — |
| DS Research | Louisville, Kentucky, United States | — |
| Cyn3rgy Research | New Brighton, Minnesota, United States | — |
| Cyn3rgy Research | Gresham, Oregon, United States | — |
| Bellaire Dermatology Associates | Bellaire, Texas, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04936113